UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 208

Sortiert nach

Autoimmune biomarkers in porto‐sinusoidal vascular disease: Potential role in its diagnosis and pathophysiology

Liver international, 2021-09, Vol.41 (9), p.2171-2178

2021

Volltextzugriff (PDF)

Second cancers in MPN: Survival analysis from an international study

American journal of hematology, 2020-03, Vol.95 (3), p.295-301

2020

Volltextzugriff (PDF)

The role of serum erythropoietin level and jak2 v617f allele burden in the diagnosis of polycythaemia vera

British journal of haematology, 2014-11, Vol.167 (3), p.411-417

2014

Volltextzugriff (PDF)

Clinical Characteristics and Outcomes of Patients with Primary and Secondary Myelofibrosis According to the Genomic Classification Using Targeted Next-Generation Sequencing

Cancers, 2023-07, Vol.15 (15), p.3904

2023

Volltextzugriff (PDF)

Development and validation of a sequential two-step algorithm for the screening of individuals with potential polycythaemia vera

Scientific reports, 2021-01, Vol.11 (1), p.209-209, Article 209

2021

Volltextzugriff (PDF)

Risk of thrombosis and hemorrhage in patients with polycythemia vera and atrial fibrillation treated with prophylactic oral anticoagulants

Annals of hematology, 2016-10, Vol.95 (11), p.1903-1904

2016

Volltextzugriff (PDF)

Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients

British journal of haematology, 2011-02, Vol.152 (4), p.413-419

2011

Volltextzugriff (PDF)

Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature

British journal of haematology, 2004-11, Vol.127 (4), p.399-403

2004

Volltextzugriff (PDF)

Essential thrombocythaemia: A contemporary approach with new drugs on the horizon

British journal of haematology, 2024-05, Vol.204 (5), p.1605-1616

2024

Volltextzugriff (PDF)

Risk factors for non-melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera

European journal of haematology, 2016-03, Vol.96 (3), p.285-290

2016

Volltextzugriff (PDF)

Mutations in the RNA splicing machinery genes in myelofibrotic transformation of essential thrombocythaemia and polycythaemia vera

British journal of haematology, 2014-02, Vol.164 (4), p.605-607

2014

Volltextzugriff (PDF)

Rapidly Growing and Aggressive Cutaneous Squamous Cell Carcinomas in a Patient Treated with Ruxolitinib

Annals of Dermatology, 2019, 31(2), , pp.204-208

2019

Volltextzugriff (PDF)

Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients

British journal of haematology, 2002-09, Vol.118 (3), p.786-790

2002

Volltextzugriff (PDF)

Lack of negative impact of Philadelphia chromosome in older patients with acute lymphoblastic leukaemia in the thyrosine kinase inhibitor era: comparison of two prospective parallel protocols

British journal of haematology, 2012-11, Vol.159 (4), p.485-488

2012

Volltextzugriff (PDF)

Discrimination between tumour epithelium and stroma via perception-based features

Neurocomputing (Amsterdam), 2015-04, Vol.154, p.119-126

2015

Volltextzugriff (PDF)

Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up

Annals of hematology, 2018-03, Vol.97 (3), p.443-451

2018

Volltextzugriff (PDF)

Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations

The Lancet. Haematology, 2022-04, Vol.9 (4), p.e301-e311

2022

Volltextzugriff (PDF)

WHO‐histological criteria for myeloproliferative neoplasms: reproducibility, diagnostic accuracy and correlation with gene mutations and clinical outcomes

British journal of haematology, 2014-09, Vol.166 (6), p.911-919

2014

Volltextzugriff (PDF)

Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera

Blood, 2012-02, Vol.119 (6), p.1363-1369

2012

Volltextzugriff (PDF)

Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status

Haematologica (Roma), 2006-02, Vol.91 (2), p.169-175

2006

Volltextzugriff (PDF)

A novel ETV6::FGFR1 fusion gene in a myeloid/lymphoid neoplasm with FGFR1 rearrangement sensitive to specific FGFR1-2-3 inhibition

Leukemia & lymphoma, 2024-03, Vol.65 (3), p.394-5

2024

Volltextzugriff (PDF)

Natural killer cell receptors and ligand variants modulate response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia

HLA, 2022-02, Vol.99 (2), p.93-104

2022

Volltextzugriff (PDF)

Rapidly Growing and Aggressive Cutaneous Squamous Cell Carcinomas in a Patient Treated with Ruxolitinib

Annals of dermatology, 2019-04, Vol.31 (2), p.204-208

2019

Volltextzugriff (PDF)

1 – 25 von 208

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(198)
Mit Volltextzugriff
(195)

Publikationsform

Artikel
(205)
Berichte
(3)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(129)
Life Sciences & Biomedicine
(127)
Hematology
(109)
Humans
(104)
Male
(76)
Female
(75)
Middle Aged
(72)
Aged
(68)
Adult
(58)
Oncology
(56)
Aged, 80 And Over
(42)
Janus Kinase 2 - Genetics
(32)
Prognosis
(31)
Biological And Medical Sciences
(28)
Medical Sciences
(28)
Hematologic And Hematopoietic Diseases
(27)
Medicine
(27)
Mutation
(27)
Adolescent
(26)
Medicine & Public Health
(26)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Autoimmune biomarkers in porto‐sinusoidal vascular disease: Potential role in its diagnosis and pathophysiology

Second cancers in MPN: Survival analysis from an international study

Risk of progression in chronic phase‐chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR‐PRO study

The role of serum erythropoietin level and jak2 v617f allele burden in the diagnosis of polycythaemia vera

Clinical Characteristics and Outcomes of Patients with Primary and Secondary Myelofibrosis According to the Genomic Classification Using Targeted Next-Generation Sequencing

The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: A multicentre collaborative study

Development and validation of a sequential two-step algorithm for the screening of individuals with potential polycythaemia vera

Risk of thrombosis and hemorrhage in patients with polycythemia vera and atrial fibrillation treated with prophylactic oral anticoagulants

Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients

Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature

Essential thrombocythaemia: A contemporary approach with new drugs on the horizon

Risk factors for non-melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera

Mutations in the RNA splicing machinery genes in myelofibrotic transformation of essential thrombocythaemia and polycythaemia vera

Rapidly Growing and Aggressive Cutaneous Squamous Cell Carcinomas in a Patient Treated with Ruxolitinib

Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients

Lack of negative impact of Philadelphia chromosome in older patients with acute lymphoblastic leukaemia in the thyrosine kinase inhibitor era: comparison of two prospective parallel protocols

Discrimination between tumour epithelium and stroma via perception-based features

Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up

Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations

WHO‐histological criteria for myeloproliferative neoplasms: reproducibility, diagnostic accuracy and correlation with gene mutations and clinical outcomes

Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera

Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status

A novel ETV6::FGFR1 fusion gene in a myeloid/lymphoid neoplasm with FGFR1 rearrangement sensitive to specific FGFR1-2-3 inhibition

Natural killer cell receptors and ligand variants modulate response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia

Rapidly Growing and Aggressive Cutaneous Squamous Cell Carcinomas in a Patient Treated with Ruxolitinib

Suchergebnisse filtern